We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland

By LabMedica International staff writers
Posted on 23 Jan 2023

Siemens Healthineers (Erlangen, Germany) has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. More...

The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders. Siemens has been active in Swords since 1966, supplying medical diagnostic equipment to hospitals and laboratories. The site currently manufactures hematology and immunoassay analyzers and supports the continuous innovation of current and new products and the development of laboratory automation software, exported to more than 50 countries across all continents. Siemens will be making a multi-million-euro investment in the site, enabling clinicians to optimize patient care by bringing new levels of precision, efficiency and reliability to the diagnostic laboratories that serve them.

The investment by Siemens will span multiple years and more than double the existing engineering team, transforming the site into an innovation hub, growing knowledge, providing new training opportunities and developing a pool of expertise in immunoassay technology. The center will push the boundaries of science and engineering. Improvements to existing diagnostic techniques will enhance disease detection capabilities with the goal of delivering faster, higher precision results with improved patient insights. This will help to meet the extremely high throughput and complex needs of hospitals and laboratories in Ireland as well as globally. The project is supported by the Irish government through IDA Ireland.

“The investment at Swords will build on our existing expertise in healthcare manufacturing, adding a critical research and development focus," states Dr Dennis Gilbert, Head of R&D for Siemens Healthineers Diagnostics. "Partnering with IDA has enabled us to move forward in ways that would not have otherwise been feasible and will allow us to pioneer breakthroughs in healthcare, helping hospitals and laboratories across the globe to diagnose disease more effectively and efficiently.

Related Links:
Siemens Healthineers 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The liquid biopsy approach measures randomness in DNA methylation patterns to detect early-stage cancer signals in blood (Photo courtesy of 123RF)

Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability

Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.